Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Raw Materials (2016 - 2025)

Historic Raw Materials for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $13.5 million.

  • Harvard Bioscience's Raw Materials fell 2410.09% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 2410.09%. This contributed to the annual value of $15.3 million for FY2024, which is 90.21% down from last year.
  • Harvard Bioscience's Raw Materials amounted to $13.5 million in Q3 2025, which was down 2410.09% from $14.8 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Raw Materials ranged from a high of $19.2 million in Q2 2022 and a low of $13.5 million during Q3 2025
  • Its 5-year average for Raw Materials is $16.3 million, with a median of $15.7 million in 2023.
  • As far as peak fluctuations go, Harvard Bioscience's Raw Materials soared by 3417.57% in 2021, and later tumbled by 2410.09% in 2025.
  • Over the past 5 years, Harvard Bioscience's Raw Materials (Quarter) stood at $18.5 million in 2021, then decreased by 5.89% to $17.4 million in 2022, then decreased by 11.65% to $15.4 million in 2023, then decreased by 0.9% to $15.3 million in 2024, then fell by 11.68% to $13.5 million in 2025.
  • Its last three reported values are $13.5 million in Q3 2025, $14.8 million for Q2 2025, and $14.7 million during Q1 2025.